Gemcitabine, a widely used chemotherapeutic in pancreatic cancer, showed complete tumor reduction in PAR1-deficient mice, while wildtype tumors showed two-fold tumor reduction [78]. This evidence concerns the gene F2R and pancreatic neoplasm.